Dr Bandreddy Peranti

Peranti Biotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for the prevention and treatment of cancer and inflammatory diseases. The company was founded to commercialize the extensive research of Dr. Bandreddy S. Reddy, a prominent expert in nutritional carcinogenesis and chemoprevention. Peranti's lead programs target specific inflammatory pathways, such as the dual inhibition of COX-2 and 5-LOX, which are known to play critical roles in tumor growth and progression. Their primary focus is on colorectal cancer, aiming to provide effective and low-toxicity treatment options for high-risk patient populations. The company operates as a private entity, translating academic breakthroughs into clinical applications.